Greenovation has substantially enhanced the yields of pharmaceutical proteins produced using its moss-based BryoTechnology.
Targeted genetic modifications, improved fermentation procedures and optimized production processes mean that the new and highly productive BryoMaster cell lines can secrete higher yields of complex molecules directly into the culture medium.
This includes producing antibodies in their active form, with enhanced antibody dependent cell-mediated cytoxity (ADCC). Adding in the company’s BryoSpeed technology means that Greenovation can produce sufficient protein for quality assessment within only 7 days.
“Our intensive research efforts are now bearing fruit,” says Dr Thomas Frischmuth, CEO of Greenovation. “The recent yield improvements once again underline the viability of moss-based cGMP-production as a beneficial alternative to mammalian cells in steel-tanks.”
The moss-made proteins manufactured using Greenovation’s BryoTechnology have very high levels of glycan consistency and batch-to-batch stability. Combining the reliability of the production process and the ease of the modular single use-based approach means that BryoTechnology is prepared to face production challenges of the facility of the future.